Nonalcoholic fatty liver disease and metabolic syndrome in postmenopausal women

Gynecological Endocrinology

Volumn 30, Issue 5, 2014, Pages 325-329

  Rodrigues, Marcio H ^a,b   Bruno, Anderson S ^a   Nahas Neto, Jorge ^a   Santos, Maria Emilia S ^c   Nahas, Eliana A P ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

Menopause; Metabolic syndrome; Nonalcoholic fatty liver disease

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ESTRADIOL; FATTY ACID; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 6; LIPOPROTEIN LIPASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ADIPOCYTOKINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALTERNATIVE ENERGY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPHOSPHORYLATION; BODY FAT DISTRIBUTION; BODY MASS; CELL MEMBRANE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; ECHOGRAPHY; ELEVATED BLOOD PRESSURE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FATTY ACID OXIDATION; GENETIC PREDISPOSITION; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEPATOMEGALY; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; INSULIN BINDING; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; MENOPAUSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN; ADIPOSE TISSUE; COMPLICATION; FEMALE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADIPOKINES; ADIPOSE TISSUE; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTMENOPAUSE;

EID: 84898840575     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.875992     Document Type: Review

References (69)

1. Livingston EH, Zylke JW. Progress in obesity research. Reasons for optimism. JAMA 2012;308:1162-4
2. Flegal KM, Carroll MD, Kit BK, Ogden BK. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7
3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-9
4. Kowdley KV, Caldwell S. Nonalcoholic steatohepatitis. A twentyfirst century epidemic? J Clin Gastroenterol 2006;40:S2-4
5. Niederau C. NAFLD and NASH. In: Mauss S, Berg T, Rockstroh J, et al., eds. Hepatology. A clinical textbook. 2nd ed. Germany: Flying Publisher; 2012:427-36
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-31
7. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab 2010;12:365-83
8. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58
9. Caballería L, Auladell MA, Torán P, et al. Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study. BMC Gastroenterol 2008;8:44-50
10. Adams LA, Lymp JF, St Sauver J, et al. The Natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterol 2005;12:113-21
11. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40:S17-29
12. Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-60
13. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 Special Conference. J Hepatol 2010;53:372-84
14. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40:S5-10
15. Paschos P, Paletas K. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009;13:9-19
16. Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003;38:954-61
17. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132:112-17
18. Caballer?a L, Pera G, Rodriguez L, et al. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used. Eur J Gastroenterol Hepatol 2012;24: 1007-11
19. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterol 1998;114:842-5
20. Hijona E, Hijona L, Arenas JI, Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010;2010:837419
21. Madan K, Bhardwaj P, Thareja S, et al. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol 2006;40:930-5
22. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009;41: 615-25
23. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of nonalcoholic fatty liver disease. Q J Med 2010;103:71-83
24. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endoc Rev 2006;27:762-78
25. Dandona P, Weinstock R, Thusu K, et al. Tumor necrosis factoralpha in sera of obese patientes: fall with weight loss. J Clin Endocrinol Metab 1998;83:2907-10
26. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004;89:447-52
27. Tarantino G, Conca P, Pasanisi F, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009;21:504-11
28. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-21
29. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010;91:258S-61S.
30. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012;55:2319-26
31. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nature Med 2002;8:1288-95
32. Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152:113-18
33. Milewicz A, Jedrzejuk D, Dunajska K, Lwow F. Waist circunference and serm adiponectin levels in obese and non-obese postmenopausal women. Maturitas 2010;65:272-5
34. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes. A sistematic review and meta-analysis. JAMA 2009;302:179-88
35. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2011;33:525-40
36. Francque S, De Maeght S, Adler M, et al. High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. Results of the Belgian NAFLD registry. Acta Gastroenterol Belg 2011;74:9-16
37. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterol 2002;123: 745-50
38. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008;14:185-92
39. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a metaanalysis. Hepatol 2011;54:1082-90
40. Loria P, Adinolfi LE, Bellentani S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42:272-82
41. AGA (American Gastroenterological Association). American Gastroenterological Association Medical Position Statement: nonalcoholic fatty liver disease. Gastroenterol 2002;123:1702-4
42. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterol 2000;118:1117-23
43. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7
44. Williamson RM, Price JF, Hayes PC, et al. Prevalence and markers of advanced liver disease in type 2 diabetes. Q J Med 2012;105: 425-32
45. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterol 2011;140:124-31
46. McPherson S, Stewart SF, Henderson E, et al. Simple non-invaisve fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265-9
47. Lee CG, Carr MC, Murdoch SJ, et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 2009;94:1104-10
48. Suzuki A, Abdemalek F. Nonalcoholic fatty liver disease in women. Women?s Health 2009;5:1-13
49. Hamaguchi M, Kojima T, Ohbora A, et al. Aging is a risk factor of non alcoholic fatty liver disease in pre-menopausal women. World J Gastroenterol 2012;18:237-43
50. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, et al. Prevalence of nonalcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010;9:402-9
51. Nemoto Y, Toda K, Ono M, et al. Altered expression of fatty acidmetabolizing enzymes in aromatase-deficient mice. J Clin Invest 2000;105:1819-25
52. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res 2007;37:239-47
53. Sowers MF, Zheng H, Tomey K, et al. Changes in body composition in women over six years at idlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007;92:895-901
54. Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 2004;5:197-216
55. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and fat distribution. Int J Obes Relat Metab Disord 2000;24:226-31
56. Zhang C, Rexrode KM, van Dam RM, et al. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality. Sixteen years of follow-up in US women. Circulation 2008;117:1658-67
57. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 update. Circulation 2007;115:1481-501
58. Schneider JG, Tompkins C, Blumenthal RS, Mora S. The metabolic syndrome in women. Cardiol Rev 2006;14:286-91
59. Meigs JB. Epidemiology of the metabolic syndrome. Am J Manag Care 2002;8:283-92
60. Nahas EAP, Padoani NP, Nahas-Neto J, et al. Metabolic syndrome and its associated risk factors in Brazilian postmenopausal women. Climacteric 2009;12:431-8
61. NCEP. NCEP Expert Panel on the detection, evaluation, and treatment of high blood pressure in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Adult Treatment Panel III (ATP III). JAMA 2001;285: 2444-9
62. Millen BE, Pencina MJ, Kimokoti RW, et al. Nutritional risk and the metabolic syndrome in women: opportunities for preventive intervention from the Framingham Nutrition Study. Am J Clin Nutr 2006; 84:434-41
63. Olufadi R, Byrne CD. Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol 2008;61:697-706
64. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1999;15:539-53
65. International Diabetes Federation: The IDF consensus worldwide definition of metabolic syndrome, 2005. Available at: www.idf.org/ webdata/docs/Mets-def- update2006.pdf.
66. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005;51:931-38
67. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation. Circulation 2009;120:1640-5
68. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40:S34-8
69. Chen ZW, Chen LY, Dai HL, et al. Relationship between alanine aminotrasnferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B 2008;9:616-22.